Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Noxopharm Ltd

NOX.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.06

▼ -3.61%

Market Cap $17.34M · Vol 2.75K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$17.34M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

48.57

Momentum

Beta

0.09

vs Market

52W High

$0.08

27.42% below

52W Low

$0.04

54.96% above

Volume

2.75K

Avg 58.01K

P/B

22.87

Price-to-book

ROE

N/A

Return on equity

Free Float

68.25%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Noxopharm Ltd (NOX.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NOX.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-10.11%

+26.98%

+6.67%

YTD

-13.98%

-33.33%

+150.78%

-86.21%

Financials & Valuation

TTM · Annual

Total Revenue	$1.86M
Net Income	$-3,213,777.00
Revenue Growth (YoY)	+49.31%
Gross Margin	100.00%
Operating Margin	-190.08%
Net Profit Margin	-172.63%
ROE	N/A
ROA · ROIC	-85.95% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	5.58
P/B	22.87
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	307.24M

Technical Indicators

50-Day SMA	$0.06
200-Day SMA	$0.06
RSI (14)	48.57
Beta	0.09
52-Week High	$0.08
52-Week Low	$0.04

Volume Today	2.75K
Avg Daily Volume (30D)	58.01K
Relative Volume	0.05x
Volatility (10D)	87.15
Volatility (30D)	97.12
Free Float	68.25%

Analyst Consensus

N/A

Current Price $0.06

Mean Target N/A

52W Low$0.04 52W High$0.08

Current

Target

$0.04 $0.08

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00D34SWR9

ISINAU000000NOX9

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Noxopharm Limited is a clinical-stage biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA drug enhancement, and oncology). Chroma is a technology platform, which is focused on development of drug candidates based on a scaffold structure known as functionalized benzopyrans. Sofra technology platform comprises a novel class of drugs targeting inflammatory and autoimmune diseases based on oligonucleotides, the building blocks of DNA, with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-SKN is a novel drug candidate for autoimmune diseases that targets an inflammatory sensor called TLR7.